X4 Pharmaceuticals News and Activities

X4 Pharmaceuticals is a company listed under the stock ticker XFOR (US).

View the org chart displaying its 17 main executives

Most searched biographies at X4 Pharmaceuticals

• Paula Ragan, Chief Executive Officer and Director
• Gary Bridger, Director
• Keith Woods, Director

Popular executive movements at X4 Pharmaceuticals

• John Volpone has joined the company as President and Chief Operating Officer  (posted on September 17 2025).
• David Kirske has joined the company as Chief Financial Officer  (posted on September 17 2025).
• Mary DiBiase, Chief Operating Officer, has left the company  (posted on September 17 2025).

Click here to view some more movements at X4 Pharmaceuticals

Create your alert
to follow the executive moves at X4 Pharmaceuticals.

X4 Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by X4 Pharmaceuticals

• X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 | X4 Pharmaceuticals, Inc.
• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | X4 Pharmaceuticals, Inc.
• View more press releases Close

Social media about X4 Pharmaceuticals

• X4 Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• X4 Pharmaceuticals on LinkedIn, X (Twitter) & YouTube